Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $8
Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $8
Canaccord Genuity维持对Cardiol Therapeutics的买入,将目标股价提高至8美元
Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $6 to $8.
Canaccord Genuity分析师爱德华·纳什维持Cardiol Therapeutics(纳斯达克股票代码:CRDL)的买入并将目标股价从6美元上调至8美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。